NEWS

The two companies are now working to expand the Clinical Development Program to the US

In order to tackle the serious health emergency caused by the COVID-19 pandemic, Kedrion ‘s R&D department set to work immediately to develop potential therapies in the shortest possible time. In this respect, our efforts are concentrated on the use of “convalescent plasma” donated by patients who have recovered from the disease.  The plasma, rich in anti-virus antibodies, undergoes pathogen

In accordance with international, national and local authority guidelines, Kedrion has acted immediately in dealing with the epidemiological emergency linked to the spread of the novel Coronavirus, and has taken all necessary measures to safeguard the health and safety of its employees and guarantee the continuation of business activities. Paolo Marcucci, Chairman & CEO has stated:

Milan, 24th  February 2020 – Società Italiana per le Imprese all’Estero – SIMEST S.p.A. (SIMEST) has today become a minority shareholder of Kedrion Biopharma Inc. (Kedrion Biopharma) with a stake of 4.5% by means of payment of a capital increase of Kedrion Biopharma of USD equivalent of Euro 10 million. Kedrion S.p.A. (Kedrion) will hold the

A Phase 3, Multi-Center Study to Assess a 10% Ig in Adults with Primary Immunodeficiency Disease

1st Annual International Meeting for Global Eradication of Rh Disease

Distribution Timed to Meet Spring/Summer Demand

U.S. Approval of RhoGAM®, Rho(D) Immune Globulin